[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f63k1hZvBOSyQTf0V4mnduFTPLOLAdT1Ll6VgVm5tnG4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"First Affiliated Hospital of Fujian Medical University",[4],85,false,43,1,49998,34,36,[14,17,19,22,25,27,30,33],{"name":15,"count":16},"Tumor",7,{"name":18,"count":16},"Positron-Emission Tomography",{"name":20,"count":21},"Prostate Cancer",5,{"name":23,"count":24},"Prostate Cancer (Adenocarcinoma)",4,{"name":26,"count":24},"Malignant Neoplasm",{"name":28,"count":29},"Total Knee Arthroplasty",3,{"name":31,"count":32},"Glaucoma",2,{"name":34,"count":32},"Spontaneous Intracerebral Hemorrhage",[36,41,46,51,56,61,66,71,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05284318","Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.","2023-12-31","Antibiotics treatment",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06520319","Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET\u002FCT in Patients With Medullary Thyroid Carcinoma","2024-12","68Ga-MGS5",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06455761","68Ga-DOTA-NI-FAPI04 PET\u002FCT in Patients With Various Types of Cancer","2025-04-01","68Ga-DOTA-NI-FAPI04",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06438250","68Ga-JH04 PET\u002FCT: Dosimetry and Biodistribution Studies","2025-05-01","68Ga-JH04",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06688188","68Ga-JH12 PET\u002FCT: Dosimetry and Biodistribution Study","2025-06-30","68Ga-JH12",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06688305","68Ga-NI-FAPI PET\u002FCT: First-in-human Study","2025-07-31","68Ga-NI-FAPI",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06612580","68Ga-AAZTA-NI-093 PET\u002FCT: First-in-human Study","2025-08-31","68Ga-AAZTA-NI-093",{"nctId":72,"briefTitle":73,"date":69,"intervention":74},"NCT06636617","177Lu-JH04 in Patients with FAP-Positive Tumors","3.70 GBq (100 mCi) of 177Lu-JH04",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06734572","18F-FAPIBiotin PET\u002FCT: Dosimetry and Biodistribution Study","2025-10-01","18F-FAPIBiotin",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06791083","Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","2025-12","Envafolimab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,142,168,192,210,237,255,278,299,317,341,369,387,405,423,444,482,504,523,543,565,583,601,626,644,663,681,700,718,744,771,793,818,836,861,886,909,934,957,984,1009,1030,1054,1078,1101,1126,1160,1193,1218,1243,1266,1284,1308,1332,1355,1380],{"intervention":94,"totalTrials":29,"cells":95},"68Ga-PSMA-11",{"EARLY_PHASE1":96,"PHASE1":109,"PHASE2":111,"PHASE3":125,"PHASE4":138,"NA":140},{"trials":97,"activeCount":108},[98],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":107},"NCT04831541","68Ga-PSMA-11 PET\u002FCT in Patients With Various Types of Cancer","UNKNOWN",[86],"2024-12-30","2020-10-10",600,[20,18],[94],0,{"trials":110,"activeCount":108},[],{"trials":112,"activeCount":9,"soonestReadout":118},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT07117760","Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","ACTIVE_NOT_RECRUITING",[87,88],"2027-12-31","2029-12-31","2025-04-22",16,[20],[124,94],"225Ac-LNC1011",{"trials":126,"activeCount":9,"soonestReadout":132},[127],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT07209878","68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","RECRUITING",[88,89],"2025-12-31","2026-06-30","2020-01-10",100,[23],[94],{"trials":139,"activeCount":108},[],{"trials":141,"activeCount":108},[],{"intervention":124,"totalTrials":32,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":145,"activeCount":108},[],{"trials":147,"activeCount":108},[],{"trials":149,"activeCount":32,"soonestReadout":154},[150,158],{"nctId":151,"briefTitle":152,"status":130,"phases":153,"primaryCompletion":154,"completion":118,"start":49,"enrollment":155,"conditions":156,"interventions":157},"NCT07363486","Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer",[87,88],"2026-12-31",9,[20],[124],{"nctId":114,"briefTitle":115,"status":116,"phases":159,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":160,"interventions":161},[87,88],[20],[124,94],{"trials":163,"activeCount":108},[],{"trials":165,"activeCount":108},[],{"trials":167,"activeCount":108},[],{"intervention":169,"totalTrials":9,"cells":170},"68Ga-G21",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":186,"PHASE4":188,"NA":190},{"trials":172,"activeCount":108},[],{"trials":174,"activeCount":108},[],{"trials":176,"activeCount":9,"soonestReadout":154},[177],{"nctId":178,"briefTitle":179,"status":130,"phases":180,"primaryCompletion":154,"completion":118,"start":181,"enrollment":182,"conditions":183,"interventions":184},"NCT07363382","The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer",[87,88],"2025-12-20",6,[23],[169,185],"68Ga-G23",{"trials":187,"activeCount":108},[],{"trials":189,"activeCount":108},[],{"trials":191,"activeCount":108},[],{"intervention":185,"totalTrials":9,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":204,"PHASE4":206,"NA":208},{"trials":195,"activeCount":108},[],{"trials":197,"activeCount":108},[],{"trials":199,"activeCount":9,"soonestReadout":154},[200],{"nctId":178,"briefTitle":179,"status":130,"phases":201,"primaryCompletion":154,"completion":118,"start":181,"enrollment":182,"conditions":202,"interventions":203},[87,88],[23],[169,185],{"trials":205,"activeCount":108},[],{"trials":207,"activeCount":108},[],{"trials":209,"activeCount":108},[],{"intervention":211,"totalTrials":9,"cells":212},"68Ga-PSMA-CYC",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":231,"PHASE4":233,"NA":235},{"trials":214,"activeCount":108},[],{"trials":216,"activeCount":108},[],{"trials":218,"activeCount":9,"soonestReadout":223},[219],{"nctId":220,"briefTitle":221,"status":130,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT07056790","Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer",[87,88],"2027-02","2027-05","2025-05-15",40,[228],"Prostate CA",[211,230],"CYC",{"trials":232,"activeCount":108},[],{"trials":234,"activeCount":108},[],{"trials":236,"activeCount":108},[],{"intervention":230,"totalTrials":9,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":240,"activeCount":108},[],{"trials":242,"activeCount":108},[],{"trials":244,"activeCount":9,"soonestReadout":223},[245],{"nctId":220,"briefTitle":221,"status":130,"phases":246,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":247,"interventions":248},[87,88],[228],[211,230],{"trials":250,"activeCount":108},[],{"trials":252,"activeCount":108},[],{"trials":254,"activeCount":108},[],{"intervention":256,"totalTrials":9,"cells":257},"68Ga-P16-093",{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":259,"activeCount":108},[],{"trials":261,"activeCount":108},[],{"trials":263,"activeCount":9,"soonestReadout":132},[264],{"nctId":265,"briefTitle":266,"status":130,"phases":267,"primaryCompletion":132,"completion":133,"start":268,"enrollment":269,"conditions":270,"interventions":271},"NCT07209865","68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI",[87,88],"2024-10-01",50,[23],[256],{"trials":273,"activeCount":108},[],{"trials":275,"activeCount":108},[],{"trials":277,"activeCount":108},[],{"intervention":84,"totalTrials":9,"cells":279},{"EARLY_PHASE1":280,"PHASE1":282,"PHASE2":284,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":281,"activeCount":108},[],{"trials":283,"activeCount":108},[],{"trials":285,"activeCount":9,"soonestReadout":83},[286],{"nctId":81,"briefTitle":82,"status":130,"phases":287,"primaryCompletion":83,"completion":224,"start":288,"enrollment":226,"conditions":289,"interventions":291},[88],"2024-06-20",[290],"Gastric Cancer",[84,292],"Fruquintinib",{"trials":294,"activeCount":108},[],{"trials":296,"activeCount":108},[],{"trials":298,"activeCount":108},[],{"intervention":292,"totalTrials":9,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":302,"activeCount":108},[],{"trials":304,"activeCount":108},[],{"trials":306,"activeCount":9,"soonestReadout":83},[307],{"nctId":81,"briefTitle":82,"status":130,"phases":308,"primaryCompletion":83,"completion":224,"start":288,"enrollment":226,"conditions":309,"interventions":310},[88],[290],[84,292],{"trials":312,"activeCount":108},[],{"trials":314,"activeCount":108},[],{"trials":316,"activeCount":108},[],{"intervention":318,"totalTrials":9,"cells":319},"177Lu-P17-088",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":321,"activeCount":108},[],{"trials":323,"activeCount":108},[],{"trials":325,"activeCount":9,"soonestReadout":118},[326],{"nctId":327,"briefTitle":328,"status":130,"phases":329,"primaryCompletion":118,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT07562438","Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer",[88],"2028-12-31","2026-04-29",20,[20],[318],{"trials":336,"activeCount":108},[],{"trials":338,"activeCount":108},[],{"trials":340,"activeCount":108},[],{"intervention":342,"totalTrials":9,"cells":343},"Adebrelimab",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":345,"activeCount":108},[],{"trials":347,"activeCount":9,"soonestReadout":352},[348],{"nctId":349,"briefTitle":350,"status":130,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":357},"NCT06181032","A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies",[87],"2029-02-23","2023-12-23",35,[356],"Biliary Tract Malignancies",[342,358,359,360],"Apatinib","Gemcitabine","Cisplatin",{"trials":362,"activeCount":108},[],{"trials":364,"activeCount":108},[],{"trials":366,"activeCount":108},[],{"trials":368,"activeCount":108},[],{"intervention":358,"totalTrials":9,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":372,"activeCount":108},[],{"trials":374,"activeCount":9,"soonestReadout":352},[375],{"nctId":349,"briefTitle":350,"status":130,"phases":376,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":377,"interventions":378},[87],[356],[342,358,359,360],{"trials":380,"activeCount":108},[],{"trials":382,"activeCount":108},[],{"trials":384,"activeCount":108},[],{"trials":386,"activeCount":108},[],{"intervention":359,"totalTrials":9,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":390,"activeCount":108},[],{"trials":392,"activeCount":9,"soonestReadout":352},[393],{"nctId":349,"briefTitle":350,"status":130,"phases":394,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":395,"interventions":396},[87],[356],[342,358,359,360],{"trials":398,"activeCount":108},[],{"trials":400,"activeCount":108},[],{"trials":402,"activeCount":108},[],{"trials":404,"activeCount":108},[],{"intervention":360,"totalTrials":9,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":408,"activeCount":108},[],{"trials":410,"activeCount":9,"soonestReadout":352},[411],{"nctId":349,"briefTitle":350,"status":130,"phases":412,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":413,"interventions":414},[87],[356],[342,358,359,360],{"trials":416,"activeCount":108},[],{"trials":418,"activeCount":108},[],{"trials":420,"activeCount":108},[],{"trials":422,"activeCount":108},[],{"intervention":45,"totalTrials":9,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":426,"activeCount":108},[],{"trials":428,"activeCount":9,"soonestReadout":44},[429],{"nctId":42,"briefTitle":43,"status":130,"phases":430,"primaryCompletion":44,"completion":431,"start":432,"enrollment":332,"conditions":433,"interventions":435},[87],"2025-07","2023-06-21",[434],"Medullary Thyroid Carcinoma",[45],{"trials":437,"activeCount":108},[],{"trials":439,"activeCount":108},[],{"trials":441,"activeCount":108},[],{"trials":443,"activeCount":108},[],{"intervention":445,"totalTrials":29,"cells":446},"68Ga-FAPI\u002F18F-FDG",{"EARLY_PHASE1":447,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":480},{"trials":448,"activeCount":32,"soonestReadout":49},[449,459,467],{"nctId":450,"briefTitle":451,"status":101,"phases":452,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT06455735","68Ga-JH04 PET\u002FCT in Patients With Various Types of Cancer",[86],"2025-12-01","2026-04-01","2024-03-01",30,[15],[55,445],{"nctId":460,"briefTitle":461,"status":130,"phases":462,"primaryCompletion":463,"completion":154,"start":455,"enrollment":456,"conditions":464,"interventions":465},"NCT06740240","68Ga-FAPI-Biotin PET\u002FCT in Patients With Various Types of Cancer",[86],"2026-06-01",[15],[466,445],"68Ga-FAPI-Biotin",{"nctId":47,"briefTitle":48,"status":130,"phases":468,"primaryCompletion":49,"completion":132,"start":469,"enrollment":456,"conditions":470,"interventions":471},[86],"2024-04-01",[15],[50,445],{"trials":473,"activeCount":108},[],{"trials":475,"activeCount":108},[],{"trials":477,"activeCount":108},[],{"trials":479,"activeCount":108},[],{"trials":481,"activeCount":108},[],{"intervention":55,"totalTrials":32,"cells":483},{"EARLY_PHASE1":484,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":485,"activeCount":9,"soonestReadout":54},[486,490],{"nctId":450,"briefTitle":451,"status":101,"phases":487,"primaryCompletion":453,"completion":454,"start":455,"enrollment":456,"conditions":488,"interventions":489},[86],[15],[55,445],{"nctId":52,"briefTitle":53,"status":130,"phases":491,"primaryCompletion":54,"completion":132,"start":455,"enrollment":21,"conditions":492,"interventions":493},[86],[26],[55],{"trials":495,"activeCount":108},[],{"trials":497,"activeCount":108},[],{"trials":499,"activeCount":108},[],{"trials":501,"activeCount":108},[],{"trials":503,"activeCount":108},[],{"intervention":60,"totalTrials":9,"cells":505},{"EARLY_PHASE1":506,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":507,"activeCount":9,"soonestReadout":59},[508],{"nctId":57,"briefTitle":58,"status":130,"phases":509,"primaryCompletion":59,"completion":132,"start":510,"enrollment":21,"conditions":511,"interventions":512},[86],"2024-11-01",[26],[60],{"trials":514,"activeCount":108},[],{"trials":516,"activeCount":108},[],{"trials":518,"activeCount":108},[],{"trials":520,"activeCount":108},[],{"trials":522,"activeCount":108},[],{"intervention":70,"totalTrials":9,"cells":524},{"EARLY_PHASE1":525,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":526,"activeCount":9,"soonestReadout":69},[527],{"nctId":67,"briefTitle":68,"status":130,"phases":528,"primaryCompletion":69,"completion":132,"start":529,"enrollment":530,"conditions":531,"interventions":532},[86],"2024-09-01",10,[23],[70],{"trials":534,"activeCount":108},[],{"trials":536,"activeCount":108},[],{"trials":538,"activeCount":108},[],{"trials":540,"activeCount":108},[],{"trials":542,"activeCount":108},[],{"intervention":74,"totalTrials":9,"cells":544},{"EARLY_PHASE1":545,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":561,"NA":563},{"trials":546,"activeCount":9,"soonestReadout":69},[547],{"nctId":72,"briefTitle":73,"status":130,"phases":548,"primaryCompletion":69,"completion":69,"start":549,"enrollment":155,"conditions":550,"interventions":552},[86],"2024-08-21",[551],"Patients with Advanced Metastatic FAP-Positive Tumors",[74,553,554],"5.55 GBq (150 mCi) of 177Lu-JH04","7.40 GBq (200 mCi) of 177Lu-JH04",{"trials":556,"activeCount":108},[],{"trials":558,"activeCount":108},[],{"trials":560,"activeCount":108},[],{"trials":562,"activeCount":108},[],{"trials":564,"activeCount":108},[],{"intervention":553,"totalTrials":9,"cells":566},{"EARLY_PHASE1":567,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":581},{"trials":568,"activeCount":9,"soonestReadout":69},[569],{"nctId":72,"briefTitle":73,"status":130,"phases":570,"primaryCompletion":69,"completion":69,"start":549,"enrollment":155,"conditions":571,"interventions":572},[86],[551],[74,553,554],{"trials":574,"activeCount":108},[],{"trials":576,"activeCount":108},[],{"trials":578,"activeCount":108},[],{"trials":580,"activeCount":108},[],{"trials":582,"activeCount":108},[],{"intervention":554,"totalTrials":9,"cells":584},{"EARLY_PHASE1":585,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":586,"activeCount":9,"soonestReadout":69},[587],{"nctId":72,"briefTitle":73,"status":130,"phases":588,"primaryCompletion":69,"completion":69,"start":549,"enrollment":155,"conditions":589,"interventions":590},[86],[551],[74,553,554],{"trials":592,"activeCount":108},[],{"trials":594,"activeCount":108},[],{"trials":596,"activeCount":108},[],{"trials":598,"activeCount":108},[],{"trials":600,"activeCount":108},[],{"intervention":602,"totalTrials":9,"cells":603},"68Ga-dPNE",{"EARLY_PHASE1":604,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":605,"activeCount":9,"soonestReadout":132},[606],{"nctId":607,"briefTitle":608,"status":130,"phases":609,"primaryCompletion":132,"completion":610,"start":611,"enrollment":456,"conditions":612,"interventions":614},"NCT06995976","Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73",[86],"2026-03-01","2025-03-01",[613],"Malignant Tumour",[602,615],"18F-FDG",{"trials":617,"activeCount":108},[],{"trials":619,"activeCount":108},[],{"trials":621,"activeCount":108},[],{"trials":623,"activeCount":108},[],{"trials":625,"activeCount":108},[],{"intervention":615,"totalTrials":9,"cells":627},{"EARLY_PHASE1":628,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":629,"activeCount":9,"soonestReadout":132},[630],{"nctId":607,"briefTitle":608,"status":130,"phases":631,"primaryCompletion":132,"completion":610,"start":611,"enrollment":456,"conditions":632,"interventions":633},[86],[613],[602,615],{"trials":635,"activeCount":108},[],{"trials":637,"activeCount":108},[],{"trials":639,"activeCount":108},[],{"trials":641,"activeCount":108},[],{"trials":643,"activeCount":108},[],{"intervention":65,"totalTrials":9,"cells":645},{"EARLY_PHASE1":646,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":647,"activeCount":9,"soonestReadout":64},[648],{"nctId":62,"briefTitle":63,"status":130,"phases":649,"primaryCompletion":64,"completion":132,"start":650,"enrollment":226,"conditions":651,"interventions":652},[86],"2024-08-01",[26],[65],{"trials":654,"activeCount":108},[],{"trials":656,"activeCount":108},[],{"trials":658,"activeCount":108},[],{"trials":660,"activeCount":108},[],{"trials":662,"activeCount":108},[],{"intervention":466,"totalTrials":9,"cells":664},{"EARLY_PHASE1":665,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":9,"soonestReadout":463},[667],{"nctId":460,"briefTitle":461,"status":130,"phases":668,"primaryCompletion":463,"completion":154,"start":455,"enrollment":456,"conditions":669,"interventions":670},[86],[15],[466,445],{"trials":672,"activeCount":108},[],{"trials":674,"activeCount":108},[],{"trials":676,"activeCount":108},[],{"trials":678,"activeCount":108},[],{"trials":680,"activeCount":108},[],{"intervention":79,"totalTrials":9,"cells":682},{"EARLY_PHASE1":683,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":684,"activeCount":9,"soonestReadout":78},[685],{"nctId":76,"briefTitle":77,"status":130,"phases":686,"primaryCompletion":78,"completion":132,"start":687,"enrollment":21,"conditions":688,"interventions":689},[86],"2024-06-25",[26],[79],{"trials":691,"activeCount":108},[],{"trials":693,"activeCount":108},[],{"trials":695,"activeCount":108},[],{"trials":697,"activeCount":108},[],{"trials":699,"activeCount":108},[],{"intervention":50,"totalTrials":9,"cells":701},{"EARLY_PHASE1":702,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":703,"activeCount":9,"soonestReadout":49},[704],{"nctId":47,"briefTitle":48,"status":130,"phases":705,"primaryCompletion":49,"completion":132,"start":469,"enrollment":456,"conditions":706,"interventions":707},[86],[15],[50,445],{"trials":709,"activeCount":108},[],{"trials":711,"activeCount":108},[],{"trials":713,"activeCount":108},[],{"trials":715,"activeCount":108},[],{"trials":717,"activeCount":108},[],{"intervention":719,"totalTrials":9,"cells":720},"Triplet-primed PCR or Long-read sequencing",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":722,"activeCount":108},[],{"trials":724,"activeCount":108},[],{"trials":726,"activeCount":108},[],{"trials":728,"activeCount":108},[],{"trials":730,"activeCount":108},[],{"trials":732,"activeCount":9,"soonestReadout":738},[733],{"nctId":734,"briefTitle":735,"status":736,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT06979024","A Registered Observational Cohort Study of Myotonic Dystrophy Type 1","ENROLLING_BY_INVITATION",[],"2038-12","2008-01",300,[742],"Myotonic Dystrophy Type 1 (DM1)",[719],{"intervention":745,"totalTrials":9,"cells":746},"LIA with different doses of Diprospan",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":757},{"trials":748,"activeCount":108},[],{"trials":750,"activeCount":108},[],{"trials":752,"activeCount":108},[],{"trials":754,"activeCount":108},[],{"trials":756,"activeCount":108},[],{"trials":758,"activeCount":9,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":130,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":770},"NCT07337772","Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty",[91],"2028-11-01","2026-02-01",120,[767,768,769],"Adrenal Cortex Hormones","Arthroplasty, Replacement, Knee","Anesthesia, Local",[745],{"intervention":40,"totalTrials":9,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":783},{"trials":774,"activeCount":108},[],{"trials":776,"activeCount":108},[],{"trials":778,"activeCount":108},[],{"trials":780,"activeCount":108},[],{"trials":782,"activeCount":108},[],{"trials":784,"activeCount":9,"soonestReadout":39},[785],{"nctId":37,"briefTitle":38,"status":130,"phases":786,"primaryCompletion":39,"completion":154,"start":787,"enrollment":788,"conditions":789,"interventions":792},[],"2021-12-01",500,[790,791],"Periprosthetic Joint Infection","Anti-Bacterial Agents",[40],{"intervention":794,"totalTrials":9,"cells":795},"PegIFNα2b+Nucleoside analog",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":797,"activeCount":108},[],{"trials":799,"activeCount":108},[],{"trials":801,"activeCount":108},[],{"trials":803,"activeCount":108},[],{"trials":805,"activeCount":108},[],{"trials":807,"activeCount":9,"soonestReadout":610},[808],{"nctId":809,"briefTitle":810,"status":130,"phases":811,"primaryCompletion":610,"completion":812,"start":813,"enrollment":226,"conditions":814,"interventions":816},"NCT07257562","Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance",[],"2026-12-01","2025-06-01",[815],"Chronic Hepatitis B",[794,817],"PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids",{"intervention":817,"totalTrials":9,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":821,"activeCount":108},[],{"trials":823,"activeCount":108},[],{"trials":825,"activeCount":108},[],{"trials":827,"activeCount":108},[],{"trials":829,"activeCount":108},[],{"trials":831,"activeCount":9,"soonestReadout":610},[832],{"nctId":809,"briefTitle":810,"status":130,"phases":833,"primaryCompletion":610,"completion":812,"start":813,"enrollment":226,"conditions":834,"interventions":835},[],[815],[794,817],{"intervention":837,"totalTrials":9,"cells":838},"Rifampicin",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":840,"activeCount":108},[],{"trials":842,"activeCount":108},[],{"trials":844,"activeCount":108},[],{"trials":846,"activeCount":108},[],{"trials":848,"activeCount":108},[],{"trials":850,"activeCount":9,"soonestReadout":855},[851],{"nctId":852,"briefTitle":853,"status":130,"phases":854,"primaryCompletion":855,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":860},"NCT07313215","Rifampin-combined Antibiotic Therapy for Staphylococcal PJI",[91],"2027-06-30","2027-12-18","2025-11-13",428,[790],[837],{"intervention":862,"totalTrials":9,"cells":863},"neoadjuvant therapy",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":872,"NA":884},{"trials":865,"activeCount":108},[],{"trials":867,"activeCount":108},[],{"trials":869,"activeCount":108},[],{"trials":871,"activeCount":108},[],{"trials":873,"activeCount":108},[874],{"nctId":875,"briefTitle":876,"status":101,"phases":877,"primaryCompletion":878,"completion":879,"start":880,"enrollment":332,"conditions":881,"interventions":883},"NCT06003673","A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC",[90],"2024-07-01","2025-07-01","2023-07-01",[882],"Hepatocellular Carcinoma Resectable",[862],{"trials":885,"activeCount":108},[],{"intervention":887,"totalTrials":9,"cells":888},"68Ga-FAP-RGD",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":890,"activeCount":108},[],{"trials":892,"activeCount":108},[],{"trials":894,"activeCount":108},[895],{"nctId":896,"briefTitle":897,"status":101,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":269,"conditions":901,"interventions":902},"NCT05515783","68Ga-FAP-RGD PET\u002FCT : Dosimetry and Preliminary Clinical Translational Studies",[87,88],"2024-05-01","2022-05-01",[15],[887,887],{"trials":904,"activeCount":108},[],{"trials":906,"activeCount":108},[],{"trials":908,"activeCount":108},[],{"intervention":910,"totalTrials":9,"cells":911},"Rituximab",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":913,"activeCount":108},[],{"trials":915,"activeCount":108},[],{"trials":917,"activeCount":108},[918],{"nctId":919,"briefTitle":920,"status":101,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":135,"conditions":925,"interventions":927},"NCT04004819","Rituximab for HTLV-1-associated Myelopathy",[88],"2023-07","2024-07","2019-08-15",[926],"HTLV-1-associated Myelopathy",[910],{"trials":929,"activeCount":108},[],{"trials":931,"activeCount":108},[],{"trials":933,"activeCount":108},[],{"intervention":935,"totalTrials":9,"cells":936},"18F-92",{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":938,"activeCount":108},[],{"trials":940,"activeCount":108},[],{"trials":942,"activeCount":108},[943],{"nctId":944,"briefTitle":945,"status":101,"phases":946,"primaryCompletion":878,"completion":878,"start":947,"enrollment":269,"conditions":948,"interventions":950},"NCT04926272","Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease",[88],"2021-07-01",[949],"Alzheimer's Disease",[935],{"trials":952,"activeCount":108},[],{"trials":954,"activeCount":108},[],{"trials":956,"activeCount":108},[],{"intervention":958,"totalTrials":9,"cells":959},"68Ga-DOTATATE and 68Ga-FAPI",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":961,"activeCount":108},[],{"trials":963,"activeCount":108},[],{"trials":965,"activeCount":108},[966],{"nctId":967,"briefTitle":968,"status":969,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":977},"NCT05990998","A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET\u002FCT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study","COMPLETED",[87,88],"2023-08-31","2023-09-01","2022-11-20",38,[976],"Tumor Positron-Emission Tomography",[958],{"trials":979,"activeCount":108},[],{"trials":981,"activeCount":108},[],{"trials":983,"activeCount":108},[],{"intervention":985,"totalTrials":9,"cells":986},"Fingolimod 0.5 mg",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":988,"activeCount":108},[],{"trials":990,"activeCount":108},[],{"trials":992,"activeCount":108},[993],{"nctId":994,"briefTitle":995,"status":996,"phases":997,"primaryCompletion":998,"completion":998,"start":999,"enrollment":108,"conditions":1000,"interventions":1002},"NCT04280588","Fingolimod in COVID-19","WITHDRAWN",[88],"2020-07-01","2020-02-22",[1001],"Coronavirus Disease (COVID-19)",[985],{"trials":1004,"activeCount":108},[],{"trials":1006,"activeCount":108},[],{"trials":1008,"activeCount":108},[],{"intervention":1010,"totalTrials":9,"cells":1011},"68Ga-FAP-CHX",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1013,"activeCount":108},[],{"trials":1015,"activeCount":108},[],{"trials":1017,"activeCount":108},[1018],{"nctId":1019,"briefTitle":1020,"status":101,"phases":1021,"primaryCompletion":54,"completion":54,"start":900,"enrollment":269,"conditions":1022,"interventions":1023},"NCT05506566","68Ga-FAP-CHX PET\u002FCT : Dosimetry and Preliminary Clinical Translational Studies",[87,88],[15,18],[1010,1010],{"trials":1025,"activeCount":108},[],{"trials":1027,"activeCount":108},[],{"trials":1029,"activeCount":108},[],{"intervention":1031,"totalTrials":9,"cells":1032},"evolocumab",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1048,"PHASE4":1050,"NA":1052},{"trials":1034,"activeCount":108},[],{"trials":1036,"activeCount":108},[],{"trials":1038,"activeCount":108},[1039],{"nctId":1040,"briefTitle":1041,"status":101,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":456,"conditions":1045,"interventions":1047},"NCT04101643","PCSK9 Inhibitor Treatment for Patients With SPG5",[87,88],"2023-01-03","2019-09-29",[1046],"Hereditary Spastic Paraplegia Type 5",[1031],{"trials":1049,"activeCount":108},[],{"trials":1051,"activeCount":108},[],{"trials":1053,"activeCount":108},[],{"intervention":1055,"totalTrials":9,"cells":1056},"A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1058,"activeCount":108},[],{"trials":1060,"activeCount":108},[],{"trials":1062,"activeCount":108},[1063],{"nctId":1064,"briefTitle":1065,"status":969,"phases":1066,"primaryCompletion":1067,"completion":972,"start":1068,"enrollment":1069,"conditions":1070,"interventions":1071},"NCT05516329","Study of 18F-Thretide PET\u002FCT in Patients With Prostate Cancer",[87,88],"2023-03-31","2022-08-20",49,[20],[1055],{"trials":1073,"activeCount":108},[],{"trials":1075,"activeCount":108},[],{"trials":1077,"activeCount":108},[],{"intervention":1079,"totalTrials":9,"cells":1080},"68Ga-NOTA Evans Blue",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1082,"activeCount":108},[],{"trials":1084,"activeCount":108},[1085],{"nctId":1086,"briefTitle":1087,"status":101,"phases":1088,"primaryCompletion":103,"completion":103,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT05140083","68Ga-NOTA Evans Blue PET\u002FCT in Patients With Lymphatic System Related Diseases",[87],"2021-04-25",80,[18],[1079],{"trials":1094,"activeCount":108},[],{"trials":1096,"activeCount":108},[],{"trials":1098,"activeCount":108},[],{"trials":1100,"activeCount":108},[],{"intervention":1102,"totalTrials":9,"cells":1103},"68Ga-NOTA-exendin-4",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1105,"activeCount":108},[],{"trials":1107,"activeCount":108},[1108],{"nctId":1109,"briefTitle":1110,"status":101,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1117},"NCT04979611","The Clinical Application of 68Ga-NOTA-exendin-4 PET\u002FCT in Detecting Insulinoma",[87],"2025-08-01","2020-08-01",60,[1116],"Insulinoma",[1102],{"trials":1119,"activeCount":108},[],{"trials":1121,"activeCount":108},[],{"trials":1123,"activeCount":108},[],{"trials":1125,"activeCount":108},[],{"intervention":1127,"totalTrials":32,"cells":1128},"99mTc-3PRGD2",{"EARLY_PHASE1":1129,"PHASE1":1150,"PHASE2":1152,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1130,"activeCount":108},[1131,1141],{"nctId":1132,"briefTitle":1133,"status":969,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT02744729","99mTc-3PRGD2 SPECT\u002FCT in Esophagus Cancer Patients",[86],"2017-01","2015-10",29,[1139],"Esophageal Cancer",[1127],{"nctId":1142,"briefTitle":1143,"status":969,"phases":1144,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":24,"conditions":1147,"interventions":1149},"NCT02723760","99mTc-3PRGD2 SPECT\u002FCT in Rheumatoid Arthritis Patients",[86],"2018-12","2015-11",[1148],"Rheumatoid Arthritis",[1127],{"trials":1151,"activeCount":108},[],{"trials":1153,"activeCount":108},[],{"trials":1155,"activeCount":108},[],{"trials":1157,"activeCount":108},[],{"trials":1159,"activeCount":108},[],{"intervention":1161,"totalTrials":32,"cells":1162},"68Ga-FAPI-04",{"EARLY_PHASE1":1163,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1164,"activeCount":108},[1165,1175],{"nctId":1166,"briefTitle":1167,"status":101,"phases":1168,"primaryCompletion":971,"completion":1169,"start":1170,"enrollment":269,"conditions":1171,"interventions":1174},"NCT04533828","68Ga-FAPI PET\u002FCT in Liver Fibrosis Patients",[86],"2023-12-30","2020-09-01",[1172,1173],"Liver Fibrosis","Positron Emission Tomography",[1161],{"nctId":1176,"briefTitle":1177,"status":101,"phases":1178,"primaryCompletion":469,"completion":469,"start":1179,"enrollment":788,"conditions":1180,"interventions":1182},"NCT04831034","68Ga-FAPI PET\u002FCT in Patients With Various Fibrotic Disease",[86],"2021-04-01",[1181,18],"Fibrosis",[1161],{"trials":1184,"activeCount":108},[],{"trials":1186,"activeCount":108},[],{"trials":1188,"activeCount":108},[],{"trials":1190,"activeCount":108},[],{"trials":1192,"activeCount":108},[],{"intervention":1194,"totalTrials":9,"cells":1195},"Deferiprone treated",{"EARLY_PHASE1":1196,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1197,"activeCount":108},[1198],{"nctId":1199,"briefTitle":1200,"status":101,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":21,"conditions":1205,"interventions":1207},"NCT04184453","Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients",[86],"2022-10-23","2022-11-23","2019-12-23",[1206],"Aceruloplasminemia",[1194],{"trials":1209,"activeCount":108},[],{"trials":1211,"activeCount":108},[],{"trials":1213,"activeCount":108},[],{"trials":1215,"activeCount":108},[],{"trials":1217,"activeCount":108},[],{"intervention":1219,"totalTrials":9,"cells":1220},"68Ga-Pentixafor",{"EARLY_PHASE1":1221,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1222,"activeCount":108},[1223],{"nctId":1224,"briefTitle":1225,"status":101,"phases":1226,"primaryCompletion":44,"completion":44,"start":1227,"enrollment":269,"conditions":1228,"interventions":1232},"NCT04504526","Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases",[86],"2020-08-07",[1229,1230,1231],"Lymphoma","Multiple Myeloma","Leukemia",[1219],{"trials":1234,"activeCount":108},[],{"trials":1236,"activeCount":108},[],{"trials":1238,"activeCount":108},[],{"trials":1240,"activeCount":108},[],{"trials":1242,"activeCount":108},[],{"intervention":1244,"totalTrials":9,"cells":1245},"68Ga-AAZTA-093",{"EARLY_PHASE1":1246,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1247,"activeCount":108},[1248],{"nctId":1249,"briefTitle":1250,"status":101,"phases":1251,"primaryCompletion":878,"completion":268,"start":469,"enrollment":456,"conditions":1252,"interventions":1254},"NCT06437496","68Ga-AAZTA-093 PET\u002FCT: First-in-human Study",[86],[1253],"Malignant Neoplasm of Prostate",[1244,1255],"68Ga-PSMA-11\u002F\u002F68Ga-PSMA-617",{"trials":1257,"activeCount":108},[],{"trials":1259,"activeCount":108},[],{"trials":1261,"activeCount":108},[],{"trials":1263,"activeCount":108},[],{"trials":1265,"activeCount":108},[],{"intervention":1255,"totalTrials":9,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1274,"PHASE2":1276,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":108},[1270],{"nctId":1249,"briefTitle":1250,"status":101,"phases":1271,"primaryCompletion":878,"completion":268,"start":469,"enrollment":456,"conditions":1272,"interventions":1273},[86],[1253],[1244,1255],{"trials":1275,"activeCount":108},[],{"trials":1277,"activeCount":108},[],{"trials":1279,"activeCount":108},[],{"trials":1281,"activeCount":108},[],{"trials":1283,"activeCount":108},[],{"intervention":1285,"totalTrials":9,"cells":1286},"Gallium-68 NODAGA-JR11",{"EARLY_PHASE1":1287,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1288,"activeCount":108},[1289],{"nctId":1290,"briefTitle":1291,"status":101,"phases":1292,"primaryCompletion":1293,"completion":1293,"start":1294,"enrollment":135,"conditions":1295,"interventions":1297},"NCT04897542","Gallium-68 NODAGA-JR11 PECT\u002FCT in Neuroendocrine Tumors",[86],"2023-12-01","2020-12-01",[1296],"Neuroendocrine Tumors",[1285],{"trials":1299,"activeCount":108},[],{"trials":1301,"activeCount":108},[],{"trials":1303,"activeCount":108},[],{"trials":1305,"activeCount":108},[],{"trials":1307,"activeCount":108},[],{"intervention":1309,"totalTrials":9,"cells":1310},"18F-T807",{"EARLY_PHASE1":1311,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1312,"activeCount":108},[1313],{"nctId":1314,"briefTitle":1315,"status":101,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":269,"conditions":1319,"interventions":1321},"NCT04926259","Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders",[86],"2024-12-01","2021-11-01",[1320],"Neurodegenerative Disorders",[1309],{"trials":1323,"activeCount":108},[],{"trials":1325,"activeCount":108},[],{"trials":1327,"activeCount":108},[],{"trials":1329,"activeCount":108},[],{"trials":1331,"activeCount":108},[],{"intervention":1333,"totalTrials":9,"cells":1334},"68Ga-DOTA\u002FNOTA-FAPI-04",{"EARLY_PHASE1":1335,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1336,"activeCount":108},[1337],{"nctId":1338,"briefTitle":1339,"status":101,"phases":1340,"primaryCompletion":1169,"completion":1169,"start":1341,"enrollment":788,"conditions":1342,"interventions":1344},"NCT04499365","68Ga-FAPI PET\u002FCT in Patients With Various Types of Cancer",[86],"2020-08-15",[15,18,1343],"Metastasis",[1333],{"trials":1346,"activeCount":108},[],{"trials":1348,"activeCount":108},[],{"trials":1350,"activeCount":108},[],{"trials":1352,"activeCount":108},[],{"trials":1354,"activeCount":108},[],{"intervention":1356,"totalTrials":9,"cells":1357},"[68Ga]Ga-P15-041",{"EARLY_PHASE1":1358,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1359,"activeCount":108},[1360],{"nctId":1361,"briefTitle":1362,"status":101,"phases":1363,"primaryCompletion":1364,"completion":132,"start":1365,"enrollment":456,"conditions":1366,"interventions":1369},"NCT06455722","[68Ga]Ga-P15-041 PET\u002FCT in Variety of Bone Tumors",[86],"2024-12-31","2024-01-01",[1367,1368],"Bone Tumor","Bone Metastases",[1356],{"trials":1371,"activeCount":108},[],{"trials":1373,"activeCount":108},[],{"trials":1375,"activeCount":108},[],{"trials":1377,"activeCount":108},[],{"trials":1379,"activeCount":108},[],{"intervention":1381,"totalTrials":9,"cells":1382},"Nusinersen",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1384,"activeCount":108},[],{"trials":1386,"activeCount":108},[],{"trials":1388,"activeCount":108},[],{"trials":1390,"activeCount":108},[],{"trials":1392,"activeCount":108},[],{"trials":1394,"activeCount":108},[1395],{"nctId":1396,"briefTitle":1397,"status":101,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":1401,"conditions":1402,"interventions":1404},"NCT05187260","Antisense Oligonucleotide for Spinal Muscular Atrophy",[],"2024-01-31","2022-01-01",1000,[1403],"Spinal Muscular Atrophy",[1381]]